(Q34340775)

1 August 2017

title

Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection (English)

1 reference

1 August 2017

0 references

0 references

1 reference

6

Sina Bavari

1 reference

1 August 2017

1

Kelly L Warfield

1 reference

1 August 2017

4

Alan L Schmaljohn

1 reference

1 August 2017

5

M Javad Aman

1 reference

1 August 2017

3

Diane L Negley

1 reference

1 August 2017

2

Dana L Swenson

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

1 August 2017

1 reference

1 August 2017

volume

22

1 reference

1 August 2017

issue

25-26

1 reference

1 August 2017

page(s)

3495-3502

1 reference

Marburg-virus disease in Kenya

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Infection and activation of monocytes by Marburg and Ebola viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Viral replication and host gene expression in alveolar macrophages infected with Ebola virus (Zaire strain)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Human asymptomatic Ebola infection and strong inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Early immune responses accompanying human asymptomatic Ebola infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Inflammatory responses in Ebola virus-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Marburg virus vaccines: comparing classical and new approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Structures of virus and virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Ebola virus-like particles protect from lethal Ebola virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Epitopes involved in antibody-mediated protection from Ebola virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Immunization for Ebola virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Vaccine research efforts for filoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Development of a preventive vaccine for Ebola virus infection in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Cytotoxic T lymphocytes, chemokines and antiviral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Infectivity-enhancing antibodies to Ebola virus glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Antibody-dependent enhancement of Ebola virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Marburg and Ebola viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

Molecular biology and evolution of filoviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.063

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.01.063

1 reference

1 August 2017

1 reference